HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Poractant alfa versus beractant for respiratory distress syndrome in preterm infants: a retrospective cohort study.

AbstractAIM:
Poractant alfa and beractant are the commonly used animal derived surfactants in preterm infants with respiratory distress syndrome. Between 2005 and 2007, poractant alfa and beractant were alternated every month in our neonatal intensive care unit for 27 months. The aim of this study was to compare the outcomes of preterm infants who received poractant alfa versus beractant.
METHOD:
Single-centre, retrospective cohort study of inborn preterm infants <32 weeks gestation (23-31(+6) ).
RESULTS:
Six hundred sixty-four preterm infants (<32 weeks) were born during the study period, of which 415 received surfactant (poractant alfa: 214; beractant: 201). Infants in the poractant alfa group were 2.8 days younger than beractant (27.0 ± 2.3 vs. 27.4 ± 2.3 weeks; P = 0.03). All other baseline characters including Clinical Risk Index for Babies II scores were similar for both groups. No significant differences were found for the following outcomes: death or chronic lung disease (78/212 vs. 59/200; P = 0.28); death (24/214 vs. 15/201, P = 0.24); moderate to severe chronic lung disease (63/212 vs. 46/200; P = 0.45) and moderate to severe disability (20/163 vs. 19/151, P = 0.98) between poractant alfa and beractant, respectively.
CONCLUSIONS:
The results of our study do not support the need for preferential use of poractant alfa or beractant.
AuthorsSaritha Paul, Shripada Rao, Rolland Kohan, Judy McMichael, Noel French, Guicheng Zhang, Karen Simmer
JournalJournal of paediatrics and child health (J Paediatr Child Health) Vol. 49 Issue 10 Pg. 839-44 (Oct 2013) ISSN: 1440-1754 [Electronic] Australia
PMID23802801 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2013 The Authors. Journal of Paediatrics and Child Health © 2013 Paediatrics and Child Health Division (Royal Australasian College of Physicians).
Chemical References
  • Biological Products
  • Phospholipids
  • Pulmonary Surfactants
  • poractant alfa
  • beractant
Topics
  • Biological Products (therapeutic use)
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Phospholipids (therapeutic use)
  • Pulmonary Surfactants (therapeutic use)
  • Respiratory Distress Syndrome, Newborn (drug therapy, mortality)
  • Retrospective Studies
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: